These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9466234)

  • 1. Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up.
    Perry R; Pataki C; Munoz-Silva DM; Armenteros J; Silva RR
    J Child Adolesc Psychopharmacol; 1997; 7(3):167-79. PubMed ID: 9466234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
    Shea S; Turgay A; Carroll A; Schulz M; Orlik H; Smith I; Dunbar F
    Pediatrics; 2004 Nov; 114(5):e634-41. PubMed ID: 15492353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study.
    McDougle CJ; Holmes JP; Bronson MR; Anderson GM; Volkmar FR; Price LH; Cohen DJ
    J Am Acad Child Adolesc Psychiatry; 1997 May; 36(5):685-93. PubMed ID: 9136504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs.
    Turgay A; Binder C; Snyder R; Fisman S
    Pediatrics; 2002 Sep; 110(3):e34. PubMed ID: 12205284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone.
    Masi G; Cosenza A; Mucci M; Brovedani P
    J Clin Psychiatry; 2003 Sep; 64(9):1039-47. PubMed ID: 14628979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open trial of risperidone in 24 young children with pervasive developmental disorders.
    Masi G; Cosenza A; Mucci M; Brovedani P
    J Am Acad Child Adolesc Psychiatry; 2001 Oct; 40(10):1206-14. PubMed ID: 11589534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching to aripiprazole in subjects with pervasive developmental disorders showing tolerability issues with risperidone.
    Ishitobi M; Hiratani M; Kosaka H; Takahashi T; Mizuno T; Asano M; Murata T; Tomoda A; Wada Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Apr; 37(1):128-31. PubMed ID: 22245026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of risperidone in pervasive developmental disorders: a case series.
    Fisman S; Steele M
    J Child Adolesc Psychopharmacol; 1996; 6(3):177-90. PubMed ID: 9231311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial.
    Van Bellinghen M; De Troch C
    J Child Adolesc Psychopharmacol; 2001; 11(1):5-13. PubMed ID: 11322745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders.
    Hellings JA; Zarcone JR; Valdovinos MG; Reese RM; Gaughan E; Schroeder SR
    J Child Adolesc Psychopharmacol; 2005 Dec; 15(6):885-92. PubMed ID: 16379508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study.
    Wake R; Miyaoka T; Inagaki T; Furuya M; Ieda M; Liaury K; Kishi K; Horiguchi J
    J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):329-36. PubMed ID: 23782127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders.
    McDougle CJ; Holmes JP; Carlson DC; Pelton GH; Cohen DJ; Price LH
    Arch Gen Psychiatry; 1998 Jul; 55(7):633-41. PubMed ID: 9672054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study.
    Di Martino A; Melis G; Cianchetti C; Zuddas A
    J Child Adolesc Psychopharmacol; 2004; 14(2):207-18. PubMed ID: 15319018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation.
    Zuddas A; Di Martino A; Muglia P; Cianchetti C
    J Child Adolesc Psychopharmacol; 2000; 10(2):79-90. PubMed ID: 10933118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability and safety profile of risperidone in a sample of children and adolescents.
    Margari L; Matera E; Craig F; Petruzzelli MG; Palmieri VO; Pastore A; Margari F
    Int Clin Psychopharmacol; 2013 Jul; 28(4):177-83. PubMed ID: 23689836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective assessment of topiramate in children and adolescents with pervasive developmental disorders.
    Hardan AY; Jou RJ; Handen BL
    J Child Adolesc Psychopharmacol; 2004; 14(3):426-32. PubMed ID: 15650499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report.
    Lombroso PJ; Scahill L; King RA; Lynch KA; Chappell PB; Peterson BS; McDougle CJ; Leckman JF
    J Am Acad Child Adolesc Psychiatry; 1995 Sep; 34(9):1147-52. PubMed ID: 7559308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder.
    Hollander E; Wasserman S; Swanson EN; Chaplin W; Schapiro ML; Zagursky K; Novotny S
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):541-8. PubMed ID: 17069543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and tolerability of switching to aripiprazole from risperidone in subjects with autism spectrum disorders: a prospective open-label study.
    Ishitobi M; Kosaka H; Takahashi T; Yatuga C; Asano M; Tanaka Y; Ueno K; Okazaki R; Omori M; Hiratani M; Tomoda A; Wada Y
    Clin Neuropharmacol; 2013; 36(5):151-6. PubMed ID: 24045605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders.
    Reyes M; Buitelaar J; Toren P; Augustyns I; Eerdekens M
    Am J Psychiatry; 2006 Mar; 163(3):402-10. PubMed ID: 16513860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.